About Us

Contact Us

Add Favorite
Home About Us Product News Order Career Contact

                                                                                                            

           APIs&Intermediates Chemicals of Shanghai APIs Chemical Co., Ltd 

           

             

 

Product Indentification
 

 

Name:   GPX150
Synonyms:   GPX150;5-imino-13-deoxydoxorubicin. (8R,10S)-10-((2S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-7,8,9,10-tetrahydrotetracen-5(12H)-one

(8R,10S)-10-(((2S,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-7,8,9,10-tetrahydrotetracen-5(12H)-one

CAS Registry Number:   236095-29-7
Molecular Formula:   C27H32N2O9
Molecular Weight:    528.21
Molecular Structure:    

 

 

 

 

 

Information about this agent


GPX-150 is a synthetic non-cardiotoxic analogue of the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Anthracycline analogue GPX-150 intercalates DNA and impedes the activity of topoisomerase II, inducing single and double-stranded breaks in DNA; inhibiting DNA replication and/or repair, transcription, and protein synthesis; and activating tumor cell apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).


As of August 2010, GPX-150 is under Phase I clinical trials sponsored by Coronado Biosciences, Inc. This is a Phase 1 safety and dose escalation study to define the maximum tolerated dose (MTD) and identify the dose limiting toxicities (DLT) following IV administration of GPX-150 once every 3 weeks. Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment. (source: http://clinicaltrials.gov/ct2/show/NCT00710125).



Current developer: Gem Pharmaceuticals, Inc and ACCESS Oncology, Inc.

 

 

 

 

 

Home About Us Product News Order Career Contact
 Copyright @ 2010-2011 APIs All rights reserved
 

 

 

No_Right_Click

 

No_Right_Click